JAMES C. WADE, M.D.; BARBARA NEWTON, R.N.; COLIN McLAREN, Ph.D.; NANCY FLOURNOY, M.S.; RONALD E. KEENEY, M.D.; JOEL D. MEYERS, M.D.
Acyclovir, a new antiviral agent, was compared to a placebo in a randomized double-blind trial of treatment for culture-proven herpes simplex virus infection after marrow transplantation. Patients received either intravenous acyclovir at 750 mg/m2 body surface area per day or a placebo for 7 days. Thirteen of 17 patients given acyclovir had a beneficial response as compared with two of 17 given the placebo (p < 0.01). The duration of positive cultures was shorter among acyclovir recipients (3 versus 17 days, p < 0.00005). Also shorter were the median days to resolution of pain (10 versus 16 days, p = 0.03), to crusting of lesions (7 versus 14 days, p = 0.01), and to total healing (14 versus 28 days, p = 0.03). No acyclovir toxicity was observed. Recurrent infection was common. Acyclovir provided significant antiviral and clinical efficacy without toxicity in highly immunosuppressed patients but had no effect on virus latency.
WADE JC, NEWTON B, McLAREN C, FLOURNOY N, KEENEY RE, MEYERS JD. Intravenous Acyclovir to Treat Mucocutaneous Herpes Simplex Virus Infection After Marrow Transplantation: A Double-Blind Trial. Ann Intern Med. ;96:265–269. doi: 10.7326/0003-4819-96-3-265
Download citation file:
Published: Ann Intern Med. 1982;96(3):265-269.
Hematology/Oncology, Infectious Disease.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use